NCT05396612Recruiting

Role of the Immune Environment in Response to Therapy in Breast Cancer

Abramson Cancer Center at Penn Medicine

Start Date

10/3/2022

Completion Date

12/31/2032

Summary

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion criteria: Women 18 years of age or older with non-metastatic breast cancer undergoing surgical resection in the University of Pennsylvania Health System. Exclusion criteria: Males Children Pregnant individuals

Interventions

OTHER

Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Breast CancerER Positive Breast CancerHER2-negative Breast CancerTNBC - Triple-Negative Breast Cancer

Locations

Abramson Cancer Center

Philadelphia, Pennsylvania 19104

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.